Home Cart Sign in  
Chemical Structure| 1621999-82-3 Chemical Structure| 1621999-82-3

Structure of CC-90003
CAS No.: 1621999-82-3

Chemical Structure| 1621999-82-3

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

CC-90003 is an irreversible inhibitor of ERK 1/2 with antitumor activity.

Synonyms: CC-90003

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of CC-90003

CAS No. :1621999-82-3
Formula : C22H21F3N6O2
M.W : 458.44
SMILES Code : C=CC(NC1=CC(C)=CC=C1NC2=NC(NC3=CC(OC)=NC=C3C)=NC=C2C(F)(F)F)=O
Synonyms :
CC-90003
MDL No. :MFCD31692404

Safety of CC-90003

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P280-P301+P312-P302+P352-P305+P351+P338

Related Pathways of CC-90003

MAPK

Isoform Comparison

Biological Activity

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT02313012 Neoplasm Metastasis PHASE1 TERMINATED 2016-05-03 Cedars Sinai Medical Center, I... More >>nflammatory Bowel Disease Center, Los Angeles, California, 90048, United States|Smilow Cancer Center, New Haven, Connecticut, 06510, United States|Levine Cancer Institute, Charlotte, North Carolina, 28204, United States|Sarah Cannon Cancer Center, Nashville, Tennessee, 37203, United States|Peter MacCallum Cancer Centre, Melbourne, 3000, Australia Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.18mL

0.44mL

0.22mL

10.91mL

2.18mL

1.09mL

21.81mL

4.36mL

2.18mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2
 

Historical Records

Categories